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Asymptomatic Coronary Artery Disease 
in a Pregnant Patient
A Case Report and Review of Literature
J. Stewart Collins, Eduardo Bossone, Kim A. Eagle, Rajendra H. Mehta1
Background: Acute myocardial infarction during pregnancy
has been reported and has been shown to be associated with
poor maternal and fetal outcomes. However, the vast majority
of these patients do not have previously recognized ischemic
heart disease. Pregnancy and delivery pose significant cardiac
stress and risk to the mother and fetus. However, it is un-
known how available therapies can be utilized in the pregnant
patient with identified ischemic heart disease to minimize
these risks. 
Case Report: We present a 39-year-old asymptomatic diabetic
female with a positive stress echocardiogram at 16 weeks of
pregnancy who remained asymptomatic throughout preg-
nancy with medical management and went on to have a nor-
Asymptomatische koronare Herzkrankheit bei einer Schwangeren. Fallbericht und Literaturübersicht
Hintergrund: Tritt ein akuter Herzinfarkt während der
Schwangerschaft auf, ist die Prognose für Mutter und Kind
ungünstig. Die Mehrheit dieser Patientinnen hat in der Vorge-
schichte keine koronare Herzerkrankung. Die Schwanger-
schaft und Geburt bedeuten eine starke kardiale Belastung
und ein Risiko für Mutter und Kind. Unbekannt ist jedoch bis-
her, welche Therapien schwangeren Patientinnen angeboten
werden können, die eine ischämische Herzerkrankung haben,
um das Risiko zu mindern.
Fallbericht: Es wird über eine 39-jährige asymptomatische
diabetische Patientin berichtet, die ein positives Belastungs-
echokardiogramm 16 Wochen nach Schwangerschaftsbeginn
aufwies und die während der Schwangerschaft unter Therapie
asymptomatisch blieb. Während der Geburt entwickelte die
Patientin einen kleinen ST-Hebungs-Infarkt mit Lungenödem
durch die erfolgte Volumenbelastung. Eine sofort durch-
geführte Herzkatheteruntersuchung zeigte eine Mehrge-
fäßerkrankung, die operativ 1 Monat nach der Geburt versorgt
wurde.
Zusammenfassung: Anhand dieses Fallbeispiels wird aufge-
zeigt, wie Patienten mit ischämischer koronarer Herzerkran-
kung während der Schwangerschaft betreut werden. Die
mögliche medikamentöse Therapie während der Schwanger-
schaft wird dargestellt. Die Möglichkeit der Revaskularisation
wird diskutiert und Empfehlungen zur Geburt und zu Stress-
tests bei solchen Patienten gegeben.
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mal vaginal delivery in the process suffering a small non-ST el-
evation myocardial infarction with pulmonary edema follow-
ing delivery due to volume overload. She ultimately under-
went cardiac catheterization and successful four-vessel CABG
1 month after her delivery. 
Conclusion: We present this patient to suggest a successful
strategy of managing a patient with non-revascularized
asymptomatic coronary artery disease during pregnancy. In
addition to reviewing the appropriate medical therapy during
pregnancy, we discuss the data on revascularization proce-
dures as well as recommendations for delivery and stress test-
ing for such patients. 
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Introduction
There are several reports of acute myocardial infarction
(AMI) complicating pregnancy that have been associat-
ed with poor maternal and fetal outcomes [1, 2]. Most of
these myocardial infarctions have been a result of coro-
nary dissection rather than ruptured plaque or in-
creased stress of pregnancy in patients with stable coro-
nary artery disease. There is only one case report of suc-
cessful pregnancy following myocardial ischemia in a
patient with newly diagnosed coronary artery disease
[3]. Given the current trend toward childbearing later in
life, we anticipate that this scenario will be seen more
frequently especially in those patients with multiple risk
factors. However, currently there is a paucity of litera-
ture providing information on the best diagnostic and
management strategies for such patients. 
We present a case of a successful vaginal delivery at
term in a patient with multiple cardiac risk factors with
a positive exercise stress echocardiogram at 16 weeks of
pregnancy. This case is presented to discuss the poten-
tial management options and demonstrate one strategy
that was successful.
Case Report
A 39-year-old female with a history of type I diabetes
mellitus of 32 years duration complicated by neuropa-
thy, hypertension, and hyperlipidemia presented to her
endocrinologist 13 weeks pregnant complaining of right
leg paresthesias. She denied any leg swelling or erythe-
ma, chest pain, shortness of breath, orthopnea, palpita-
tions, dizziness, lightheadedness or syncope. Her activi-
ty was limited by leg cramps after walking two blocks or
climbing two flights of stairs. She reported no prior his-
tory of coronary artery disease, peripheral vascular dis-
ease, or stroke. Her diabetes was well controlled with a
hemoglobin A1C of 6.4 and hypertension was con-
trolled on atenolol 50 mg once a day with blood pressure
of 110/60 mm Hg. Her lipid profile consisted of a LDL
of 120 mg/dl, HDL 59 mg/dl, and triglycerides 270 mg/dl
while taking simvastatin. However, this was discontin-
ued during prenancy. She had a 15-pack-year smoking
history but quit 2 years ago and had no family history of
premature coronary artery disease. 
Physical examination was unremarkable and her
electrocardiogram was normal. A stress electrocardio-
gram was ordered by her endocrinologist which re-
vealed 2 mm of down-sloping ST depression in leads II,
III, aVF, and V3–V6 at 3 minutes post exercise which re-
solved 9 minutes post exercise. She exercised 8.5 min-
utes to stage 7 of Cornell protocol stopping secondary to
fatigue and achieving max Mets 8.9 and PRP 245. 
She was referred to cardiology at 16 weeks pregnan-
cy at which time the impression was the she had multiple
risk factors for coronary artery disease in the absence of
any symptoms with a positive stress ECG. Her cardiolo-
gist reviewed her history, physical examination, and the
stress ECG and felt that the abnormal stress ECG could
indicate either ischemia or a false positivity due to left
ventricular hypertrophy from her longstanding hyper-
tension. An exercise stress echocardiogram was per-
formed and the patient stopped at 10 minutes/stage 5 of
Cornell protocol secondary to fatigue and achieved 7.0
Mets and PRP 216. Her baseline echocardiogram was
normal but her stress echocardiographic images re-
vealed hypokinesis of the anterior wall, distal 2/3 of lat-
eral wall and apex consistent with large territory of in-
ducible ischemia. 
At this point, there was a debate among her physi-
cians regarding the safety of continuing pregnancy. The
cardiologist felt that as the patient was asymptomatic,
she could be safely managed through her pregnancy
with aggressive medical treatment and close follow-up,
while her obstetrician felt that the risk of continuing
pregnancy to the mother and fetus was high and recom-
mended abortion. As no further guidance was provided
for either strategy from the review of literature at this
point, these options were discussed with the patient and
she elected for the strategy of medical treatment be-
cause of her strong desire to continue her pregnancy.
Although catheterization was a consideration, it was de-
cided that it would be best performed if the mother de-
veloped any untoward adverse event while continuing
her pregnancy. 
The patient remained asymptomatic throughout
pregnancy on a regimen of methyldopa 250 mg po tid,
atenolol 75 mg po qd, insulin, isosorbide mononitrate 30
mg po qd, aspirin 81 mg po qd, and colesevelam (a new
bile-acid binding resin-trade name Welchol) 3 tabs po
qd. 
The patient underwent a forceps assisted vaginal
delivery after 8 hours of labor with epidural anesthesia
giving birth to a completely healthy baby. As a result of
the intravenous fluids received in the peripartum peri-
od, she had a net 3 liters of positive fluid balance over
the next 24 hours. She consequently developed acute
shortness of breath the next day after her delivery. A
chest X-ray at that point revealed pulmonary edema
and an ECG showed approximately 1 mm of ST depres-
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sion in leads V3–V6. Her troponin peaked at 5.7 (nor-
mal < 2.0) and a surface echocardiogram showed an
ejection fraction of 50% with an area of apical and ante-
rior hypokinesis. 
She was treated aggressively with diuretics, nitrates,
and an angiotensin converting enzyme inhibitor and re-
sponded rapidly to this therapy and was ambulating
without difficulty the following day with normal oxy-
genation. Given the fact that she had significant vaginal
bleeding, she was discharged home on metoprolol,
lisinopril, ASA, simvastatin, and insulin to be followed
closely by her cardiologist with further work-up of her
coronary artery disease at a later time when she had re-
cuperated from her pregnancy and her vaginal bleeding
had stopped. 
She remained stable after discharge on medical
management and underwent cardiac catheterization 4
weeks postpartum. Left ventriculography showed an
ejection fraction of 60% without wall motion abnormal-
ities or mitral regurgitaton. Coronary angiography re-
vealed a left dominant system with a 70% mid left main
stenosis, 100% mid LAD, 70% ostial first diagonal,
60–69% ostial circumflex, and a 70% mid circumflex le-
sion. The right coronary artery was non-dominant and
free of disease. 
2 weeks later she underwent a four-vessel coronary
artery bypass graft surgery with a left internal mamma-
ry artery to the left anterior descending coronary artery,
and saphenous vein grafts to the second diagonal, ob-
tuse marginal and left posterolateral branch. 
Discussion
Potential Strategy for Managing Asymptomatic
Coronary Artery Disease Based on our Patient
Pregnant patients at high risk for coronary artery disease
should be screened non-invasively. We report that a
strategy of aggressive medical therapy and close follow-
up of a patient with even severe asymptomatic coronary
artery disease can help carry her safely through pregnan-
cy without any increased risk to mother or fetus. Al-
though it is difficult to make generalized recommenda-
tions for all such patients based on one case, it suggests
that medical management is a reasonable option with
cardiac catheterization reserved for patients that be-
come unstable during follow-up. Importantly, given the
significant morbidity and mortality with myocardial in-
farction during pregnancy, it is prudent to evaluate for
coronary artery disease especially in those at high risk.
Symptoms are often absent or often dismissed as being
part of a normal pregnancy. Such detection of the pres-
ence of coronary artery disease in a pregnant patient will
allow for aggressive modification of risk and result in
better outcomes as seen in our patient. 
We cannot speculate how this patient and her baby
would have done if an invasive strategy was adopted at
the beginning, when first seen by her cardiologist. Sur-
prisingly, we found scant data on pregnant patients with
asymptomatic coronary artery disease on review of the
literature, providing no guidelines on management of
such patients and calling for a common sense approach
that is tailored for individual patients. 
Coronary Artery Disease in Pregnancy
There have been two large reviews of the literature re-
garding myocardial infarction during pregnancy [1, 2].
Hankins et al [1] report 68 cases of myocardial infarc-
tion during pregnancy with an overall maternal mortali-
ty of 37% and a fetal mortality of 34%. The maternal
mortality was highest in the third trimester (45%) and
when delivery occurred within 14 days of initial myocar-
dial infarction (47%). However, only 13% of the
women were known to have coronary artery disease pri-
or to pregnancy. The review by Roth et al [2], which
studied 125 patients and also included the postpartum
period, reports an overall maternal mortality of 21%
and infant mortality of 12%. Maternal mortality was
highest in the peripartum (35%) and postpartum (30%)
period. Only 7% of these patients had previously docu-
mented ischemic heart disease. Maternal mortality is
particularly high among diabetic (IDDM) pregnancies
complicated by myocardial infarction with death occur-
ring in half of these patients [4]. Although this mortality
data concern for maternal safety in the case presented,
it should be remembered that our patient was asympto-
matic from her coronary artery disease and her peripar-
tum risk was modified by aggressive medical manage-
ment because her disease was detected early. 
Diagnosis of Ischemic Heart Disease
Recommendations for stress testing during pregnancy
should be in accordance with the American College of
Cardiology and the American Heart Association guide-
lines for stress testing in patients with coronary artery
disease [5]. However, it should be noted that the safety
of stress testing during pregnancy has not been fully es-
tablished. Animal studies have shown decreased uterine
blood flow during heavy exercise without adverse fetal
effects. A study of eight women at 35–38 weeks preg-
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nancy showed a 30% increase in uterine artery imped-
ance with exercise to 85% maximum heart rate. There
was no fetal bradycardia [6]. However, another study
showed 3/18 fetal bradycardic events with maximum ex-
ercise without adverse fetal outcome [7]. These findings
have led to recommendations that exercise stress testing
during pregnancy should be done with fetal monitoring
with a goal of exercise to 70% maximum heart rate [8].
Echocardiography is safe during pregnancy and should
be the imaging modality of choice for pregnant patients
undergoing stress testing. There are no reports of phar-
macologic stress testing during pregnancy. Dobutamine
is listed as pregnancy category B (Table 1) [9], but there
are no reports of its use during pregnancy. Animal stud-
ies have shown no teratogenic effects. Adenosine has
been used in pregnancy for termination of supraventric-
ular tachycardias without alteration of fetal heart rate
or other serious fetal or maternal toxicity [10–13].
Dipyridamole has also been used during pregnancy in
conjunction with aspirin for patients with prosthetic
heart valves. In one report, four normal pregnancies re-
sulted in neonates of normal weight without congenital
abnormalities [14]. Another report of eight patients in-
cluded six live births (one with incurving fifth fingers bi-
laterally), one 13-week abortion, and a second abortion
at 22 weeks after 9 weeks of warfarin therapy [15].
Radiation exposure is an important issue with nu-
clear stress testing and cardiac catheterization. Radia-
tion exposure during organ formation (10–50 days) may
cause teratogenesis and generally should be avoided if
possible. Beyond this period, there are still risks of in-
trauterine growth retardation and central nervous sys-
tem abnormalities along with potential increased risk of
malignancy. High level fluoroscopy or cine-radiography
could deliver 5–10 rad/minute or radiation. Exposure to
the uterus and embryo should be minimized with the
use of lead apron. It is believed the uterus/embryo ab-
sorb less than 5% of the radiation. Exposure to less than
10 rad is considered low risk, but termination of preg-
nancy is recommended for exposure over 15 rad. Car-
diac nuclear imaging with thallium or sestamibi is asso-
ciated with fetal radiation of 1–2 rad [8]. Nevertheless, it
should be avoided if there are safer alternatives. Rou-
tine cardiac catheterization also poses little risk, but
percutaneous intervention prolongs the cine time lead-
ing to significant radiation exposure.
Medical Therapy
Aspirin is considered safe at doses less than 150 mg per
day in the second and third trimesters, although the
safety of its use in the first trimester is a source of an on-
going debate [16]. Prior reports have raised concern for
maternal and fetal hemorrhage [17], congenital abnor-
malities (abnormal septation of the truncus arteriosus),
and more importantly, premature closure of the ductus
arteriosus at higher doses [18]. However, a metaanalysis
of eleven studies did not show an increased risk of pla-
cental abruption or perinatal mortality at doses less
than 200 mg per day [19]. Although aspirin is secreted in
breast milk, it has not been shown to cause any adverse
side effects in infants.
Beta blockers: There have been no reports of terato-
genesis with use of beta blockers. Concern for intrauter-
ine growth retardation exists although there are no de-
finitive studies establishing such an association. Pruyn
et al [20] studied twelve pregnancies with long-term
propranolol therapy and noted that only one infant was
above the 50th percentile in either weight or head cir-
cumference. Additionally, five of the twelve infants
were at the 10th percentile or less for head circumfer-
ence. However, prospective studies of 94 pregnancies
demonstrated only four infants with intrauterine
growth retardation [21]. Several case reports exist with
neonatal bradycardia, hypoglycemia, apnea at birth,
and hyperbilirubinemia associated with propranolol
use, although there have been no permanent sequelae.
Larger observations do not statistically correlate these
events with beta blockers. It has also been suggested
that beta-1 agents are preferred as non-selective beta
A Controlled studies in women fail to demonstrate a risk to the fetus in
the first trimester, and the possibility of fetal harm appears remote. 
B Animal studies do not indicate a risk to the fetus and there are no
controlled human studies, or animal studies do show an adverse ef-
fect on the fetus but well-controlled studies in pregnant women have
failed to demonstrate a risk to the fetus. 
C Studies have shown that the drug exerts animal teratogenic or em-
bryocidal effects, but there are no controlled studies in women, or no
studies are available in either animals or women. 
D Positive evidence of human fetal risk exists, but benefits in certain
situations (eg, life-threatening situations or serious diseases for
which safer drugs cannot be used or are ineffective) may make use of
the drug acceptable despite its risks. 
X Studies in animals or humans have demonstrated fetal abnormalities
or there is evidence of fetal risk based on human experience, or both,
and the risk clearly outweighs any possible benefit.
Table 1. United States Food and Drug Administration (FDA) pregnancy
risk category definition.
Tabelle 1. Definition der Schwangerschaftrisikokategorien nach 
United States Food and Drug Administration (FDA).
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blockers that may facilitate uterine contractions [2]. Be-
ta blockers are also secreted in breast milk and can
cause bradycardia in an infant requiring careful moni-
toring of their heart rate in nursing mothers. 
Angiotensin Converting Enzyme (ACE) Inhibitors:
Second and third trimester use is contraindicated and
has been associated with serious neonatal adverse ef-
fects including renal failure, oligohydramnios, neonatal
anuria, intrauterine growth retardation, premature la-
bor, bony malformations, limb contracture, persistent
patent ductus arteriosus, pulmonary hypoplasia, respi-
ratory distress syndrome, and fetal wasting. Limb and
craniofacial deformities result from oligohydramnios
rather than teratogenicity of these agents. The cause-ef-
fect relationship is further confounded by the fact that
women being treated with ACE inhibitors are typically
those with high-risk pregnancies [22]. It has been sug-
gested that the toxicity is not seen if use is limited to the
first trimester [23]. Skull bone hypoplasia that has been
most commonly reported with first trimester use is pre-
sumably from oligohydramnios and hypotension [24].
Nevertheless, women planning pregnancy should switch
to other antihypertensive or vasodilating agents when
on an ACE inhibitor for either hypertension or left ven-
tricular dysfunction. ACE inhibitors are not secreted in
breast milk and as such can be safely administered to
nursing mothers. 
Lipid Lowering Agents: Statins are considered ter-
atogenic and should be avoided during pregnancy. A re-
port of 134 pregnancies with inadvertent exposure to lo-
vastatin or simvastatin resulted in normal outcomes in
85%, congenital anomalies 4.0%, spontaneous abor-
tions 8.0%, fetal deaths/stillbirths 1.0%, and miscella-
neous adverse outcomes in 2.0% [25]. Another report of
169 women exposed to simvastatin led to 66 normal
births, 40 requested induced abortions, twelve sponta-
neous abortions, four premature newborns, three new-
borns with malformations, and two fetal deaths [26].
The authors of these studies report these outcomes to
be comparable to outcomes in the general population,
but use of statins remains contraindicated in pregnancy.
Niacin and gemfibrozil are both listed as category C.
Niacin is generally not recommended for pregnancy, al-
though there are no reports of adverse effects in preg-
nancy. Gemfibrozil has been safely used in a pregnant
patient with lipoatrophic diabetes mellitus, although da-
ta about its use among pregnant patients in general are
limited [27]. Bile acid sequestrants are category B (see
Table 1) [9] and considered safe.
Antiplatelet Agents: Limited data exist on the safety
of newer antiplatelet agents during pregnancy. Ticlopi-
dine has been used safely following PTCA/stenting at 25
weeks pregnancy in one patient without IIb/IIIa in-
hibitors [28] and at 38 weeks in another with abciximab
[29]. There have been no reports of the use of clopido-
grel with or without IIb/IIIa inhibitors, although both
are listed as category B for pregnancy (see Table 1) [9]. 
Anticoagulation: Warfarin has long been known to
be teratogenic and should not be used during pregnan-
cy, especially between the 6th and 12th weeks of gesta-
tion. One third of 418 pregnancies in which coumadin
was used resulted in fetal abnormalities. Adverse effects
include hemorrhagic complications, embryopathy
(greatest between 6th and 12th weeks), and central ner-
vous system abnormalities [30]. Heparin does not cross
the placenta and can be used safely. Ginsberg et al [31]
reported a study of 98 pregnancies with heparin therapy
and showed no differences in terms of prematurity, still-
birth, abortions, deaths, or congenital abnormalities
from normal population. Heparin should be discontin-
ued with the onset of labor. Low molecular weight he-
parin does not cross the placenta and is probably a rea-
sonable alternative to unfractionated heparin but dos-
ing information is not known and because of its longer
half life may require reversing of its effect during pre-
cipitous or spontaneous delivery to minimize maternal
blood loss [16].
Other Agents: Nitrates and diuretics have been used
safely in pregnancy. However, careful monitoring for
maternal hypotension is warranted to avoid uteropla-
cental insufficiency and fetal distress. Digoxin is consid-
ered safe, both during pregnancy and in the postpartum
period. It does cross the placenta and has been used to
treat maternal and fetal arrhythmias. Nifedipine is the
calcium channel blocker of choice and has been used for
hypertension. Short acting nifedipine as a sole agent is
best avoided for treatment of myocardial ischemia. 
Revascularization Options
Percutaneous Interventions: Three cases of percuta-
neous transluminal coronary angioplasty without and
three cases with stent implantation have been reported
following myocardial infarction during pregnancy [28,
29, 32–35]. There were no reported maternal or fetal
deaths in these patients. None of these cases were per-
formed with the use of glycoprotein IIb/IIIa inhibitors
and clopidogrel, the current standard of care for pa-
tients undergoing percutaneous interventions. In one
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patient, abciximab was utilized in combination with
ticlopidine [29]. Further, there are no reports of percu-
taneous interventions in pregnant patients with stable
coronary artery disease.
Coronary Artery Bypass Grafting (CABG): The
largest case series reported 133 cases of open heart
surgery using cardiopulmonary bypass during pregnancy
with four maternal deaths (3%) and 25 fetal deaths
(19%) [36]. Only four of these cases involved CABG
with no maternal or fetal deaths, while the rest included
surgeries for valvular or congenital disease [37–39]. Fetal
deaths occurred mostly with aortic and mitral valve re-
placements and septal defect closures. Close fetal heart
rate monitoring is necessary as fetal bradycardia usually
corrects with increased pump flow rate and temperature.
The cardioplegic solution can cause decreased uterine
blood flow as it results in peripheral vasodilatation.
Minimizing the Stress of Delivery
Epidural anesthesia is recommended as it reduces pain
in labor, decreases preload and afterload, and decreases
cardiac stress. The mode of delivery should be primarily
determined by obstetrical reasons, rather than cardiac
condition. Among myocardial infarction during 66
pregnancies, Hankins et al [1] reported a 14% maternal
mortality with vaginal delivery versus 23% with cesare-
an section. Thus, if obstetrically indicated, vaginal deliv-
ery should be attempted. The use of vacuum or forceps
to assist delivery when possible may help avoid pro-
longed labor reducing the stress on the heart. A left lat-
eral decubitus position of the mother during labor may
help optimize hemodynamics by displacing the uterus
and increasing the venous return and cardiac output.
Use of oxygen, analgesics, nitrates, and beta blockers as
indicated to reduce myocardial oxygen demand are also
recommended. Hematocrit should be maintained at all
times above 30 mg/dl. Finally, the use of intravenous hy-
dration should be closely monitored to avoid positive
fluid balance, that like in our patient, may result in acute
decompensation from increased pre-load and oxygen
demand.
Conclusion
Our case suggests that even patients with moderate to
high risk coronary lesions who are asymptomatic can be
managed safely through pregnancy and labor with ag-
gressive medical management and close monitoring.
Further, our review of literature suggests a need for a
prospective registry of such patients to provide more in-
sight into this issue as the current trend toward child-
bearing later in life continues and increases the preva-
lence of pregnant patients with coronary artery disease
in the community at large. 
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